Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNASDAQ:IMTXNASDAQ:OGINASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$23.38+0.6%$21.64$12.21▼$41.31$682.80M-0.26634,581 shs298,242 shsIMTXImmatics$5.59+2.4%$5.21$3.30▼$13.09$663.66M0.83671,329 shs805,735 shsOGIOrganigram Global$1.40+6.1%$1.27$0.85▼$2.08$176.80M1.37656,895 shs825,752 shsURGNUrogen Pharma$13.11-4.4%$9.26$3.42▼$18.15$632.59M0.41.06 million shs2.02 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+0.60%-0.04%+16.15%+23.38%-3.47%IMTXImmatics+2.38%-4.44%+13.39%+20.73%-52.71%OGIOrganigram Global+6.06%+6.06%+4.87%+35.92%-8.20%URGNUrogen Pharma-4.45%-11.84%+233.59%+17.05%-23.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio2.1875 of 5 stars3.40.00.00.03.81.70.6IMTXImmatics2.7816 of 5 stars3.63.00.00.03.41.70.0OGIOrganigram Global0.6853 of 5 stars0.01.00.00.01.10.02.5URGNUrogen Pharma4.7288 of 5 stars4.54.00.04.52.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$42.3881.24% UpsideIMTXImmatics 3.20Buy$14.67162.37% UpsideOGIOrganigram Global 3.00BuyN/AN/AURGNUrogen Pharma 3.00Buy$32.86150.63% UpsideCurrent Analyst Ratings BreakdownLatest OGI, IMTX, ANAB, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.006/13/2025URGNUrogen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$16.006/13/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Buy$31.006/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.006/13/2025URGNUrogen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $30.006/12/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.006/3/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M7.53N/AN/A$2.33 per share10.03IMTXImmatics$168.65M4.03$0.25 per share22.35$5.12 per share1.09OGIOrganigram Global$117.47M1.60N/AN/A$2.07 per share0.68URGNUrogen Pharma$90.40M6.69N/AN/A($0.21) per share-62.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)IMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)OGIOrganigram Global-$33.39M$0.1014.00N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)Latest OGI, IMTX, ANAB, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/12/2025Q1 2025URGNUrogen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.258.25IMTXImmaticsN/A10.2810.28OGIOrganigram GlobalN/A3.421.90URGNUrogen Pharma4.775.655.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AIMTXImmatics64.41%OGIOrganigram Global34.63%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%IMTXImmatics3.30%OGIOrganigram Global0.09%URGNUrogen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million19.54 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableOGIOrganigram Global860133.94 million133.82 millionOptionableURGNUrogen Pharma20046.11 million43.76 millionOptionableOGI, IMTX, ANAB, and URGN HeadlinesRecent News About These CompaniesUrogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?June 24 at 1:45 PM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from AnalystsJune 24 at 2:43 AM | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by BrokeragesJune 24 at 2:41 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 23, 2025 | globenewswire.comLowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen†or the “Companyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJune 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 22, 2025 | prnewswire.comStocks With Rising Relative Price Strength: UroGen PharmaJune 20, 2025 | msn.comHC Wainwright Has Negative View of Urogen Pharma Q2 EarningsJune 20, 2025 | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What HappenedJune 18, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 18, 2025 | globenewswire.comHC Wainwright Decreases Earnings Estimates for Urogen PharmaJune 18, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Raised to "Buy" at HC WainwrightJune 18, 2025 | americanbankingnews.comH.C. Wainwright Sees Billion Dollar Potential in UroGen’s New TherapyJune 17, 2025 | msn.comUroGen Pharma (NASDAQ:URGN) Trading Down 7.7% - Time to Sell?June 17, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 17, 2025 | prnewswire.comUroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in MayJune 17, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Sees Strong Trading Volume on Analyst UpgradeJune 17, 2025 | americanbankingnews.comURGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered LossesJune 16, 2025 | accessnewswire.comAInvestors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGNJune 16, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGNJune 16, 2025 | accessnewswire.comAUroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst UpgradeJune 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernSoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesWall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPEGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractOGI, IMTX, ANAB, and URGN Company DescriptionsAnaptysBio NASDAQ:ANAB$23.38 +0.14 (+0.60%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$23.31 -0.07 (-0.30%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Immatics NASDAQ:IMTX$5.59 +0.13 (+2.38%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$5.52 -0.07 (-1.23%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Organigram Global NASDAQ:OGI$1.40 +0.08 (+6.06%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.38 -0.01 (-1.07%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Urogen Pharma NASDAQ:URGN$13.11 -0.61 (-4.45%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$13.12 +0.02 (+0.11%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
